Alexander Karen P, Roe Matthew T, Chen Anita Y, Lytle Barbara L, Pollack Charles V, Foody Joanne M, Boden William E, Smith Sidney C, Gibler W Brian, Ohman E Magnus, Peterson Eric D
Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA.
J Am Coll Cardiol. 2005 Oct 18;46(8):1479-87. doi: 10.1016/j.jacc.2005.05.084. Epub 2005 Sep 29.
This study evaluated the impact of age on care and outcomes for non-ST-segment elevation acute coronary syndromes (NSTE ACS).
Recent clinical trials have expanded treatment options for NSTE ACS, now reflected in guidelines. Elderly patients are at highest risk, yet have previously been shown to receive less care than younger patients.
In 56,963 patients with NSTE ACS at 443 U.S. hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) National Quality Improvement Initiative from January 2001 to June 2003, we compared use of guidelines-recommended care across four age groups: <65, 65 to 74, 75 to 84, and > or =85 years. A multivariate model tested for age-related differences in treatments and outcomes after adjusting for patient, provider, and hospital factors.
Of the study population, 35% were > or =75 years old, and 11% were > or =85 years old. Use of acute anti-platelet and anti-thrombin therapy within the first 24 h decreased with age. Elderly patients were also less likely to undergo early catheterization or revascularization. Whereas use of many discharge medications was similar in young and old patients, clopidogrel and lipid-lowering therapy remained less commonly prescribed in elderly patients. In-hospital mortality and complication rates increased with advancing age, but those receiving more recommended therapies had lower mortality even after adjustment than those who did not.
Age impacts use of guidelines-recommended care for newer agents and early in-hospital care. Further improvements in outcomes for elderly patients by optimizing the safe and early use of therapies are likely.
本研究评估年龄对非ST段抬高型急性冠状动脉综合征(NSTE ACS)的治疗及预后的影响。
近期临床试验拓展了NSTE ACS的治疗选择,目前已反映在指南中。老年患者风险最高,但此前研究表明他们接受的治疗比年轻患者少。
在2001年1月至2003年6月参与美国心脏病学会/美国心脏协会指南(CRUSADE)国家质量改进计划的443家美国医院的56963例NSTE ACS患者中,我们比较了四个年龄组(<65岁、65至74岁、75至84岁以及≥85岁)对指南推荐治疗的使用情况。在对患者、医疗服务提供者和医院因素进行调整后,采用多变量模型测试治疗和预后方面与年龄相关的差异。
研究人群中,35%的患者年龄≥75岁,11%的患者年龄≥85岁。急性抗血小板和抗凝血酶治疗在最初24小时内的使用随年龄增长而减少。老年患者接受早期导管插入术或血运重建的可能性也较小。虽然年轻和老年患者在许多出院药物的使用上相似,但老年患者中氯吡格雷和降脂治疗的处方率仍然较低。住院死亡率和并发症发生率随年龄增长而增加,但即使在调整后,接受更多推荐治疗的患者的死亡率仍低于未接受推荐治疗的患者。
年龄影响对新药物指南推荐治疗的使用以及早期住院治疗。通过优化治疗的安全早期使用,老年患者的预后可能会进一步改善。